The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic.

Today, the first global regulatory workshop on COVID-19 was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA)